Heiner H. Wedemeyer
Expertise in
17
conditions

Heiner H. Wedemeyer

Hepatology
Carl Neuberg Str, 
Hannover, NI, DE 
Expertise in
17
conditions
Carl Neuberg Str, 
Hannover, NI, DE 

Overview

Heiner Wedemeyer is a Hepatologist in Hannover, Germany. Mr. Wedemeyer is highly rated in 17 conditions, according to our data. His top areas of expertise are Hepatitis D, Hepatitis, Hepatitis C, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 701 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hepatology

Gender

Male

Locations

Carl Neuberg Str, Hannover, NI, Germany
Other Locations
Carl Neuberg Str. 1, Hannover, NI 30625, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Hepatitis B Immunoglobulins to Induce HBsAg Clearance in Patients With Chronic Hepatitis B (HBIG for Cure)
Hepatitis B Immunoglobulins to Induce HBsAg Clearance in Patients With Chronic Hepatitis B (HBIG for Cure)
Enrollment Status: Terminated
Publish Date: September 04, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Enrollment Status: Unknown
Publish Date: August 25, 2023
Intervention Type: Drug
Study Drug: Peginterferon Lambda-1a
Study Phase: Phase 3
A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir
A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir
Enrollment Status: Terminated
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
Study Phase: Phase 4
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

701 Total Publications

From the Editor's Desk...
From the Editor's Desk...
Journal: Journal of hepatology
Published: January 17, 2026

Frequently Asked Questions about Heiner H. Wedemeyer

Is Heiner H. Wedemeyer a top-rated expert for Hepatitis D?

MediFind is an objective health platform that identifies experts based on real-world data. Heiner H. Wedemeyer is classified as an Elite expert for Hepatitis D, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Heiner H. Wedemeyer specialize in?

While Heiner H. Wedemeyer is a Hepatology, they have specific expertise in Hepatitis D, Hepatitis, and Hepatitis C. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hepatology.

Does Heiner H. Wedemeyer participate in research or clinical trials?

Yes. Heiner H. Wedemeyer has published 701 articles and abstracts on conditions like Hepatitis D. You can view a list of Heiner H. Wedemeyer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wedemeyer's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile